The Wegovy FlexTouch pen: what to know before you decide

What exactly is the FlexTouch, and how does it differ from other pen formats?

The FlexTouch is Novo Nordisk's auto-injector platform. Unlike a traditional pen injector where you push a plunger with your thumb, the FlexTouch works by pressing the body of the pen against your skin until it clicks, then holding it in place until the dose is fully delivered. The needle is covered before use and retracts after, which matters to many people who feel anxious about injections.

This is the format Wegovy comes in for every dose in the standard titration ladder: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg. Each pen contains four doses, so one pen covers four weeks of treatment. The MHRA separately approved a dedicated 7.2 mg single-dose pen in April 2026, which uses a built-in covered needle and auto-dosing mechanism and is designed for one injection per week with no reuse. For the right dose and pen format at any stage, your prescriber makes that call, not the pharmacy shelf.

A question our prescribers hear most weeks is whether you can get a 2.4 mg pen and start there to save time. The titration schedule exists to reduce nausea and gastrointestinal side effects: the earlier doses settle your system before the therapeutic doses do the heavier work. The Wegovy treatment overview explains the full schedule and the clinical rationale behind it.

Choosing your injection site and what the FlexTouch format means for technique

The three recommended injection sites for Wegovy are the abdomen (keeping away from the navel), the front of the thigh, and the upper arm. You rotate between sites each week to reduce localised reactions, repeated injection into the same small area can cause skin changes over time.

The FlexTouch's auto-inject mechanism removes one variable: you don't need to calibrate how hard to press a plunger. Press the pen cap-end down firmly onto clean skin, wait for the first click, keep it pressed until the second click and then hold for a further six seconds. That sequence is the same at every dose. If you're finding that the injection site itself becomes tender or reactive, the guidance on skin sensitivity with semaglutide covers what's normal and when it warrants a call to your prescriber.

The NHS's patient information for semaglutide on the NHS medicines page covers injection technique in plain language alongside a full list of side effects to watch for. Always cross-reference with the Patient Information Leaflet supplied with your pen, since that leaflet is specific to the exact product and strength you've been prescribed.

The practical realities: storage, travel, and what happens if a dose goes wrong

Wegovy FlexTouch pens are refrigerated medicines. They need to be kept between 2 °C and 8 °C, the fridge, not the freezer. A pen that has been frozen should not be used. For brief periods outside the fridge (travel, for instance), there is a permitted room-temperature window, but the exact duration and conditions are set out in the Patient Information Leaflet and vary between products; never rely on a general figure you've read online.

If you inject and later wonder whether the dose went in correctly, or whether you've accidentally given yourself too much, the information on accidental overdose with Wegovy is worth reading. The short answer is that most injection errors don't cause serious harm, but contact your prescriber or 111 if you have concerns. The same applies if you experience an unusual reaction after a dose, the MHRA's Yellow Card scheme allows patients to report suspected side effects directly, and doing so helps build the post-market safety picture for newer medicines.

For context on how the cost of ongoing Wegovy treatment fits into a private prescription, the Wegovy cost page sets out what a legitimate private prescription typically includes and what to look for if you're comparing providers.

Deciding whether the FlexTouch format suits you, and what comes next

For most people, the FlexTouch is simply the pen Wegovy arrives in, and the auto-inject design makes it more accessible than a conventional needle-and-syringe setup. The decision that actually shapes your experience is not which pen format you use, but whether Wegovy is clinically right for you, at which dose, and with what level of support around it.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. Ethnic-background BMI thresholds may be 2.5 kg/m² lower under UK guidance. NICE recommends semaglutide within a specialist weight management pathway and for a maximum of two years, though private prescribing follows the licensed criteria directly rather than NICE's NHS commissioning route. Suitability also depends on your medical history, current medicines and other factors your prescriber reviews, and if you've come across questions about how Wegovy affects fluid balance, our page on whether Wegovy works as a diuretic addresses that topic directly. The NICE appraisal for semaglutide, TA875, covers the evidence base in full.

If you'd like to find out whether Wegovy is appropriate for you, our prescribers review consultations the same day and can answer questions about technique, dose titration and what to expect. Speak to our prescribers through a free consultation, there's no obligation and no automatic approval.